IRIS
DEL PRINCIPE, MARIA ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 37.363
AS - Asia 6.388
EU - Europa 5.653
SA - Sud America 1.000
Continente sconosciuto - Info sul continente non disponibili 869
AF - Africa 102
OC - Oceania 32
Totale 51.407
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 37.029
SG - Singapore 2.734
IT - Italia 1.714
CN - Cina 1.186
DE - Germania 824
BR - Brasile 790
RU - Federazione Russa 774
HK - Hong Kong 667
VN - Vietnam 514
IE - Irlanda 491
UA - Ucraina 443
BD - Bangladesh 409
GB - Regno Unito 316
FR - Francia 275
JP - Giappone 200
CA - Canada 199
KR - Corea 190
FI - Finlandia 187
NL - Olanda 159
SE - Svezia 150
IN - India 115
PL - Polonia 79
AR - Argentina 62
MX - Messico 58
AT - Austria 56
ID - Indonesia 52
ES - Italia 51
CO - Colombia 40
TR - Turchia 38
PH - Filippine 33
BE - Belgio 31
EC - Ecuador 31
IQ - Iraq 31
ZA - Sudafrica 30
AU - Australia 29
PK - Pakistan 26
VE - Venezuela 25
IR - Iran 23
TH - Thailandia 23
SA - Arabia Saudita 20
MY - Malesia 19
UZ - Uzbekistan 19
CL - Cile 15
CZ - Repubblica Ceca 15
JM - Giamaica 14
PY - Paraguay 14
NP - Nepal 13
CH - Svizzera 12
CR - Costa Rica 12
DZ - Algeria 12
EG - Egitto 12
IL - Israele 12
MA - Marocco 12
HN - Honduras 11
LB - Libano 11
LT - Lituania 11
PE - Perù 11
KE - Kenya 9
AE - Emirati Arabi Uniti 8
GT - Guatemala 8
TW - Taiwan 8
UY - Uruguay 8
DO - Repubblica Dominicana 7
EU - Europa 7
HR - Croazia 7
TN - Tunisia 7
AL - Albania 6
GR - Grecia 6
RO - Romania 6
RS - Serbia 6
SN - Senegal 6
A2 - ???statistics.table.value.countryCode.A2??? 5
AZ - Azerbaigian 5
NG - Nigeria 5
NI - Nicaragua 5
SK - Slovacchia (Repubblica Slovacca) 5
TT - Trinidad e Tobago 5
BY - Bielorussia 4
GE - Georgia 4
JO - Giordania 4
KZ - Kazakistan 4
LI - Liechtenstein 4
NO - Norvegia 4
PT - Portogallo 4
BB - Barbados 3
BO - Bolivia 3
HU - Ungheria 3
OM - Oman 3
BS - Bahamas 2
EE - Estonia 2
ET - Etiopia 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
MN - Mongolia 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
PS - Palestinian Territory 2
QA - Qatar 2
SV - El Salvador 2
Totale 50.522
Salva come PNG Salva come JPEG
Città #
Woodbridge 9.114
Wilmington 8.876
Houston 5.167
Singapore 1.524
Fairfield 1.321
Ashburn 1.228
San Jose 1.004
Chandler 975
Ann Arbor 732
Hong Kong 646
Seattle 545
Beijing 491
Cambridge 466
Rome 437
Dublin 409
Council Bluffs 385
New York 383
Jacksonville 357
Santa Clara 316
Dearborn 288
Medford 288
Los Angeles 236
Dallas 221
The Dalles 221
Tokyo 181
Ho Chi Minh City 161
Lawrence 136
Buffalo 127
Milan 121
Moscow 117
Lauterbourg 108
Hanoi 106
Boardman 104
Zhengzhou 100
São Paulo 76
San Diego 75
Chicago 67
Denver 58
Helsinki 57
Brooklyn 56
Munich 56
Atlanta 55
Montreal 53
Mülheim 52
Nuremberg 52
Toronto 50
Warsaw 50
Menlo Park 47
Phoenix 47
Orem 45
Bologna 44
Creede 43
Frankfurt am Main 42
London 41
North Bergen 39
Redondo Beach 35
Jakarta 34
Engelhard 33
Lappeenranta 32
Seoul 32
Da Nang 30
Shanghai 30
Naples 29
Boston 28
Brussels 27
Turin 27
Columbus 26
Redwood City 26
Chennai 25
Guangzhou 25
Rio de Janeiro 23
Florence 22
Hefei 22
Stockholm 22
Vienna 22
Bari 21
Palo Alto 21
Amsterdam 20
Belo Horizonte 20
Norwalk 20
Mexico City 19
Haiphong 18
Johannesburg 18
Poplar 18
San Francisco 17
University Park 17
Verona 17
Center 16
Las Vegas 16
Turku 16
Charlotte 15
Quito 15
Brasília 14
Campinas 14
Falls Church 14
Madrid 14
Miami 14
Nanjing 14
Philadelphia 14
Shenzhen 14
Totale 38.962
Salva come PNG Salva come JPEG
Nome #
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 651
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 549
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 523
Clinical significance of CD38 expression in chronic lymphocytic leukemia 499
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 497
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 491
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 482
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 482
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 481
NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma 465
Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study 461
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 459
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia 454
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients 453
A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia 451
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. 451
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 449
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage 449
Advances in the treatment of elderly and frail patients with acute myeloid leukemia 448
Lack of efficacy of imiquimod in patients with basal cell carcinoma previously treated with rituximab for B cell lymphoma: two case reports 444
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia 441
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 440
Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia 438
ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations 434
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia 432
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. 431
Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia 427
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 427
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 427
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation 425
The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells 424
Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23(+)/MLL+ translocation in leukaemia 424
Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes 422
Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells 420
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study 419
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia 419
Circulating regulatory T cells in clinical monoclonal B-cell lymphocytosis. 416
Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey 416
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications 416
Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. 413
A cluster of Geotrichum clavatum (Saprochaete clavata) infection in haematological patients: a first Italian report and review of literature 413
The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia 411
Monitoring of minimal residual disease in acute myeloid leukemia 410
Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome 410
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow 407
High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma 406
Treatment of low-blast count AML using hypomethylating agents 402
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 402
Treatment of Acute Myeloid Leukemia with 20-30% Bone Marrow Blasts 397
CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias 395
Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia 395
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy 393
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 393
Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia 389
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features 389
Minimal Residual Disease as Biomarker for Optimal Biologic Dosing of ARA-C in Patients with Acute Myeloid Leukemia 388
Extensive toxic epidermal necrolysis following brentuximab vedotin administration 381
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. 380
Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia 379
Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia 375
Successful treatment of disseminated fusariosis with high dose liposomal amphotericin-B in a patient with acute lymphoblastic leukemia [4] 373
Longitudinal detection of DNMT3AR882Htranscripts in patients with acute myeloid leukemia 373
Apoptosis and immaturity in acute myeloid leukemia 372
Posaconazole oral suspension primary prophylaxis in acute leukemia and allogeneic stem cell transplant patients: can it be used without measurement of plasma concentration? 372
Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia 371
Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia 370
Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. 368
Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia 368
Thrombosis in adult patients with acute leukemia 365
CD69 is independently prognostic in chronic lymphocytic leukemia: acomprehensive clinical and biological profiling study 364
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia 359
Circulating regulatory T cells in "clinical" monoclonal B-cell lymphocytosis 359
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia 359
Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia 359
Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia. 358
Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy 352
Risk allocation of adults patients with non-M3 acute myeloid leukemia 352
Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes 349
Minimal residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology? 349
In vitro elimination of EGFR-overexpressing cancer cells by CD32A chimeric receptor T cells in combination with cetuximab or panitumumab 346
Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient 339
The emerging role of measurable residual disease detection in AML in morphologic remission 339
Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the campus all network 338
Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. 336
Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling 335
FCγ chimeric receptor-engineered T cells: Methodology, advantages, limitations, and clinical relevance 334
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 323
Fludarabine, Cytarabine and Gentuzumab Ozogamicin (FLA-GO) as Salvage Therapy and Bridge to Transplant in Adult Relapsed Acute Myeloid Leukemia (AML) Patients 317
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study 314
Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse 306
Gemtuzumab ozogamicin in combination with intensive chemotherapy for relapsed/refractory acute myeloid leukemia 296
Real-life analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study 294
Case report: A Saprochaete clavata (Magnusiomyces clavatus) severe infection effectively treated with granulocyte transfusion in a young patient with myeloid sarcoma 267
Fungal infections of the central nervous system and paranasal sinuses in onco-haematologic patients. Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases 255
An evaluation of enasidenib for the treatment of acute myeloid leukemia 252
Clinical relevance of an objective - limit of detection - limit of quantification - based flow cytometry approach for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial 252
ACUTE LEUKEMIA AND LATENT TUBERCULOSIS INFECTION IN ITALY: QUANTIFERON-TB TEST SCREENING IN A LOW TUBERCULOSIS INCIDENCE COUNTRY 237
Rhodotorula infection in haematological patient: Risk factors and outcome 229
Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness 228
Antifungal effect of all-trans retinoic acid against aspergillus fumigatus in vitro and in a pulmonary aspergillosis in vivo model 225
Totale 39.119
Salva come PNG Salva come JPEG
Categoria #
all - tutte 147.442
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 147.442
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.392 0 0 0 48 33 171 100 113 139 165 92 531
2022/20232.609 286 230 230 261 157 472 288 163 285 46 134 57
2023/20241.219 104 52 135 35 99 331 57 83 43 31 35 214
2024/20254.639 181 890 531 245 85 285 403 208 485 473 391 462
2025/20269.032 860 419 990 689 858 335 1.017 1.068 1.025 731 513 527
2026/20272.545 470 416 1.454 205 0 0 0 0 0 0 0 0
Totale 51.407